do not combine glp-1 receptor agonists with dpp-4 inhibitors guideline Complete pharmacology and pharmacotherapy of in bullet points for easy understanding: DPP-4 Inhibitors –Summary 1. Drug Names (Generic / Brand) Sitagliptin – Januvia Saxagliptin – Onglyza Linagliptin – Tradjenta Alogliptin – Acute DPP-4 inhibition modulates vascular

found that GLP-1 can reduce oxidative stress in BV2 microglia by inhibiting the accumulation of intracellular ROS and release of nitric oxide (NO), as well as by increasing the expression of the antioxidant glutathione peroxidase 1 (GPx1) and superoxide dismutase 1 (SOD1) (184)

P.HollowayH

Adverse effects GLP-1RAs are generally well tolerated, but with a common set of side effects, typically affecting the gastrointestinal system

Nevertheless, the exact mechanism by which GLP-1 analogues promote IL-6 expression in monocytes is still unclear

Their ability to engage in multiple organ systems through biologically conserved pathways has not only validated their initial use in glycemic control but also catalyzed their expansion into cardiovascular, renal, and metabolic domains

1 Proposed regulatory mechanisms between silent mating type information regulation 2 homolog (SIRT1) and AMP-activated protein kinase (AMPK)